NASDAQ:UROV
Delisted
Urovant Sciences Ltd. Stock News
$16.24
+0 (+0%)
At Close: May 27, 2022
Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo
02:18pm, Friday, 13'th May 2022
Urovant Sciences' interim results from a Phase 2a trial of URO-902 gene therapy were presented at the annual meeting of the American Urological Association (AUA2022). Urovant is a wholly-owned subsi
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies -UROV, INFO, WDR, CKH, EIGI
08:30pm, Monday, 28'th Dec 2020
NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Urovant Sciences Ltd. (NASDAQ: UROV) concerning pote
GEMTESA® is the second FDA approval for the Sumitovant Biopharma family of companies in the past weekGEMTESA® is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for o
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Urovant Scie
New York, New York--(Newsfile Corp. - November 18, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.new
RM LAW Announces Investigation of Urovant Sciences Ltd.
04:15pm, Wednesday, 18'th Nov 2020
BERWYN, Pa., Nov. 18, 2020 /PRNewswire/ -- RM LAW, P.C. announces an investigation on behalf of Urovant Sciences Ltd. ("Urovant" or the "Company") (NASDAQ: UROV) regarding possible breaches of fiducia
Urovant Sciences: Buyout Price Is Too Low
09:08am, Monday, 16'th Nov 2020
The acquisition of Urovant Sciences by majority owner Sumitomo significantly undervalues the company's lead asset vibegron. The buyout price implies approximately $250 million in peak sales for vibegr
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Urovant Sciences Ltd. - UROV
08:00pm, Friday, 13'th Nov 2020
NEW YORK, Nov. 13, 2020 /PRNewswire/-- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York Ci
SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd.
03:04pm, Friday, 13'th Nov 2020
NEW YORK, Nov. 13, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Urovant Sciences Ltd. ("UROV" or the
Why Urovant Sciences Stock Is Skyrocketing Today
12:15pm, Friday, 13'th Nov 2020
The company's biggest shareholder plans to acquire all of Urovant.
UROV Stock: 9 Things to Know About the Urovant Sciences-Sumitovant Deal
10:58am, Friday, 13'th Nov 2020
Urovant Sciences (UROV) has entered into an acquisition agreement with Sumitovant Biopharma that has UROV stock soaring on Friday. The post UROV Stock: 9 Things to Know About the Urovant Sciences-Sumi
Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares
05:18pm, Thursday, 12'th Nov 2020
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares
Sumitovant Biopharma and Urovant Sciences Announce Sumitovant's Acquisition of Remaining Stake in Urovant
05:00pm, Thursday, 12'th Nov 2020
NEW YORK and LONDON and IRVINE, Calif. and BASEL, Switzerland, Nov. 12, 2020 /PRNewswire/ -- Sumitovant Biopharma and Urovant Sciences (Nasdaq: UROV) today announced that they have entered into a defi
Urovant Sciences' (UROV) CEO Jim Robinson on Q2 2020 Results - Earnings Call Transcript
10:38pm, Monday, 02'nd Nov 2020
Urovant Sciences' (UROV) CEO Jim Robinson on Q2 2020 Results - Earnings Call Transcript